EmsanaRx aims to address “the lack of accountability of the PBM industry to its employer clients."
The rate of spending increase on high-tech pharmaceuticals will top 17% for a second consecutive year, a study says.
The 420-employer National Business Group on Health recommends public-policy changes relating to the proliferating category of specialty drugs.
Health benefits costs are forecast to climb 5% next year, thanks in part to fast-rising prices for specialty pharmaceuticals.
The combination of two of the three largest U.S. drug store chains continues a wave of industry consolidation spurred by the Affordable Care Act.
Thanks to a proliferation of high-cost drugs for complex conditions, pharmacy expenses outpace overall medical cost growth.
An American fight over expensive new treatments has global implications.
